Introduction Chronic myeloid leukemia (CML) is a myelodysplastic neoplasia accounting for
around 15% of all cases of leukemia in adults. CML treatment is mainly based on tyrosine …

Abstract Background and Objectives First-line treatment of chronic phase (CP) chronic
myeloid leukemia (CML) is based on the first-generation tyrosine kinase inhibitor (TKI) …

Introduction. Imatinib is the most commonly used frontline drug in chronic phase (CP)
chronic myeloid leukemia (CML) patients worldwide. In early 2017 a generic formulation of …

Results Italian patients received 1L imatinib (IM; retrospective [(n= 31]; prospective [n= 106]),
dasatinib (DAS; n= 56) or nilotinib (NIL; n= 73). Documented cytogenetic response …

Background: Long-term use of TKIs may expose patients (pts) to significant adverse events
(AEs) that may affect quality of life. In recent years, treatment-free remission (TFR) has …

Introduction. Generic formulations of imatinib mesylate have been introduced in western
Europe and the US since 2017 for the treatment of patients affected by Chronic Myeloid …

Chronic myeloid leukemia (CML) treatment is based on company‐sponsored and academic
trials testing different tyrosine kinase inhibitors (TKIs) as first‐line therapy. These studies …

Introduction Tyrosine kinase inhibitors (TKIs) have dramatically changed the outcome of
chronic phase chronic myeloid leukemia patients (CP-CML), improving the long-term …

Abstract Background: The advent of Tyrosine Kinase Inhibitors (TKI) totally changed the
outcome of patients affected by Chronic Myeloid Leukemia (CML). Most of informations …

Introduction: therapy of chronic phase (CP) chronic myeloid leukemia (CML) is based on
tyrosine kinase inhibitors (TKIs) in virtually all patients. Three TKIs are approved for first-line …